版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Objective:To evaluate the clinical value of integrated backscatter(IBS) parameters in detecting the hepatic and renal toxicity by symphysic chemotheraphy(Paclitaxel and Cisplatin). Methods:Forty-five patients have finish
2、ed 4 cycles of TP symphysichemotherapy(Paclitaxel and Cisplatin)(21 days per cycle)or more for malignancy treatment(A group).Until the finally day of TP symphysic chemotherapy,the shortest course of treatment is four cyc
3、lese and the longest course of treatment is seven cyclese;the total minimal dos of PTX is 480mg/m2 and the total maximal dos of PTX is 840 mg/m2;the total minimal dos of DDP is 400mg/m2,the total maximal dos of DDP is 70
4、0mg/m2.And forty volunteers without liver and kidney diseases served as the control group(B group)were included in our study.The conventional ultrasonic parameters of liver and ren were respectively measured.And the conv
5、entional ultrasonic parameters were also obtainted.Obtained Parameters include:1、The conventional ultrasonic parameters:the right hepatic lengthes,portal vein inner diameters;the two renal lengthes and widthes,and thickn
6、esses of renal cortexs of the two groups.2、IBS parameters:The integrated backscatter (IBS) and examined IBS% of liver and ren of the two groups were obtained.Results1、The conventional parameters comparison:the gender、a
7、ge and hepatic sizese and renal sizese had no significantly difference between groups A and B(P>0.05).2、 IBS parameters comparision:the IBS parameters of livers in A group were significantly higher than those in B group(
8、P<0.0 1).Aecording to CTC 3.0,IBS and IBS%in group A that include patients whose livers had not damaged and those patients whose livers had damaged were significantly higher than those in B group(P<0.05,P<0.0 1).But in A
9、 group these parameters that were compared had no significantly difference (P>0.05).the IBS parameters of rens in A group were significantly higher than those in B group(P<0.01).According to CTC 3.0,IBS and IBS%in group
10、A that include patients whose rens had not damaged and those patients whose rens had damaged were significantly higher than those in B group(P<0.05,P<0.0 1).But in A group these parameters that were compared had no signi
11、ficantly difference(P>0.05).Conclusions:Integrated backscatter parameters may be valuable in the assessment of hepatic and renal toxicity by symphysic chemotheraphy(Paclitaxel and Cisplatin),especially the assessment of
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 眾賞文庫僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 紫杉醇聯(lián)合順鉑對(duì)宮頸癌新輔助化療的近期療效評(píng)價(jià).pdf
- 紫杉醇脂質(zhì)體與傳統(tǒng)紫杉醇聯(lián)合順鉑治療老年非小細(xì)胞肺癌對(duì)比研究
- 紫杉醇聯(lián)合順鉑對(duì)局部晚期宮頸鱗癌的療效研究.pdf
- 紫杉醇-順鉑同步放化療治療局部晚期鼻咽癌的臨床研究.pdf
- 宮頸癌紫杉醇聯(lián)合順鉑新輔助化療前后蛋白質(zhì)組學(xué)研究.pdf
- 紫杉醇聯(lián)合順鉑與5-Fu聯(lián)合順鉑同步放療治療食管癌的療效觀察.pdf
- 吉西他濱聯(lián)合順鉑方案與多西紫杉醇聯(lián)合順鉑方案治療晚期非小細(xì)胞肺癌的系統(tǒng)評(píng)價(jià)
- 紫杉醇聯(lián)合卡鉑對(duì)比紫杉醇聯(lián)合表阿霉素治療局部晚期三陰性乳腺癌的Ⅱ期臨床研究.pdf
- 噎膈Ⅰ號(hào)方對(duì)順鉑聯(lián)合紫杉醇方案治療中晚期食管癌增效減毒的臨床觀察研究.pdf
- 多西紫杉醇或吉西他濱聯(lián)合順鉑治療晚期非小細(xì)胞肺癌的臨床研究.pdf
- 超聲背向散射積分技術(shù)評(píng)價(jià)高血脂大鼠腎損害的實(shí)驗(yàn)研究.pdf
- 調(diào)強(qiáng)放療聯(lián)合紫杉醇及奈達(dá)鉑同步化療治療食管癌的臨床分析.pdf
- 超聲背向散射積分評(píng)價(jià)兔慢性腎衰腎損害的實(shí)驗(yàn)研究.pdf
- 順鉑逆轉(zhuǎn)鼻咽癌紫杉醇耐藥分子機(jī)制的初步研究.pdf
- 多烯紫杉醇聯(lián)合草酸鉑腹腔化療治療進(jìn)展期胃癌療效探討.pdf
- 人卵巢癌紫杉醇耐藥細(xì)胞株的建立及紫杉醇聯(lián)合化療方案的體外研究.pdf
- 心肌背向散射積分參數(shù)評(píng)價(jià)蒽環(huán)類抗腫瘤藥心臟毒性的臨床研究.pdf
- 卡鉑聯(lián)合紫杉醇治療局部晚期三陰性乳腺癌的Ⅱ期臨床研究.pdf
- 超聲背向散射積分評(píng)價(jià)糖尿病腎病的臨床研究.pdf
- 含紫杉醇的化療方案治療晚期胃癌的臨床研究.pdf
評(píng)論
0/150
提交評(píng)論